Alembic Limited (IN:ALEMBICLTD)
:ALEMBICLTD
Want to see IN:ALEMBICLTD full AI Analyst Report?
Top Page
Alembic Limited
(ALEMBICLTD)
Select Model
Select Model
Rating:74Outperform
Price Target:
₹101.00
▼(-2.32% Downside)
Action:UpgradedDate:10/24/25
Alembic Limited's strong financial performance and attractive valuation are the primary drivers of its stock score. The company's robust revenue growth and profitability metrics, combined with a low P/E ratio and reasonable dividend yield, suggest a solid investment opportunity. However, mixed technical indicators and potential sustainability concerns regarding profit metrics slightly temper the overall outlook.
Positive Factors
Strong revenue growth
A 50.8% revenue jump in 2025 indicates durable commercial traction across formulations and API lines. Sustained top-line expansion supports scale economies, funds R&D and market entry, and helps lower unit costs—strengthening structural growth potential over months.
Negative Factors
Net profit margin anomaly
An anomalous 140% net margin attributed to one‑time gains undermines the reliability of reported profitability. If core margins revert when non‑recurring items drop out, earnings, dividend capacity and reinvestment plans could materially weaken versus reported levels.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
A 50.8% revenue jump in 2025 indicates durable commercial traction across formulations and API lines. Sustained top-line expansion supports scale economies, funds R&D and market entry, and helps lower unit costs—strengthening structural growth potential over months.
Read all positive factors
Alembic Limited (ALEMBICLTD) vs. iShares MSCI India ETF (INDA)
Market Cap
₹23.45B
Dividend Yield2.36%
Average Volume (3M)22.23K
Price to Earnings (P/E)10.8
Beta (1Y)1.50
Revenue Growth14.04%
EPS Growth1.38%
CountryIN
Employees285
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)2.34
Shares Outstanding256,781,830
10 Day Avg. Volume15,327
30 Day Avg. Volume22,227
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)1.10
Price to Sales (P/S)11.55
P/FCF Ratio71.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Alembic Limited Business Overview & Revenue Model
Company Description
Alembic Limited engages in the manufacturing and marketing of fermentation and chemistry based active pharmaceuticals ingredients (API). It operates through API and Real Estate segments. The company is also involved in the construction of resident...
How the Company Makes Money
Alembic Limited primarily makes money by selling pharmaceutical products, with revenue largely derived from (1) finished dosage formulations (branded and/or generic medicines) sold into the Indian market and exported to regulated and other interna...
Alembic Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.24B | 2.22B | 1.57B | 1.18B | 713.69M | 678.37M |
| Gross Profit | 1.58B | 1.53B | 872.46M | 702.07M | 404.50M | 392.74M |
| EBITDA | 1.72B | 1.69B | 1.12B | 939.86M | 1.03B | 213.43M |
| Net Income | 3.24B | 3.11B | 2.69B | 1.91B | 2.22B | 3.43B |
Balance Sheet | ||||||
| Total Assets | 27.27B | 25.03B | 23.29B | 22.05B | 26.32B | 24.09B |
| Cash, Cash Equivalents and Short-Term Investments | 888.10M | 582.80M | 129.05M | 464.09M | 270.77M | 225.14M |
| Total Debt | 125.80M | 144.50M | 91.49M | 0.00 | 0.00 | 2.77M |
| Total Liabilities | 1.91B | 1.64B | 1.43B | 1.27B | 1.35B | 1.12B |
| Stockholders Equity | 25.36B | 23.39B | 21.86B | 20.78B | 24.97B | 22.97B |
Cash Flow | ||||||
| Free Cash Flow | 257.50M | 356.00M | -336.03M | 130.35M | -535.60M | -496.37M |
| Operating Cash Flow | 489.60M | 863.70M | 226.87M | 388.52M | -177.47M | -21.82M |
| Investing Cash Flow | 135.10M | -265.80M | 258.36M | 72.96M | 188.48M | -348.69M |
| Financing Cash Flow | -639.70M | -583.40M | -481.94M | -463.88M | -58.16M | -153.62M |
Alembic Limited Technical Analysis
Positive
103.40
Price Trends
87.54
Positive
93.14
Negative
99.79
Negative
Market Momentum
0.78
Negative
63.11
Neutral
97.82
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALEMBICLTD, the sentiment is Positive. The current price of 103.4 is above the 20-day moving average (MA) of 81.10, above the 50-day MA of 87.54, and above the 200-day MA of 99.79, indicating a neutral trend. The MACD of 0.78 indicates Negative momentum. The RSI at 63.11 is Neutral, neither overbought nor oversold. The STOCH value of 97.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ALEMBICLTD.
Alembic Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹23.45B | 10.80 | ― | 2.36% | 14.04% | 1.38% | |
74 Outperform | ₹807.05B | 18.87 | ― | 0.33% | 7.31% | 0.34% | |
73 Outperform | ₹388.40B | 27.58 | ― | 0.28% | 8.92% | 24.73% | |
72 Outperform | ₹646.14B | 25.97 | ― | 0.80% | 11.73% | 10.02% | |
57 Neutral | ₹148.31B | 31.27 | ― | 1.28% | 13.20% | 4.00% | |
53 Neutral | ₹678.85B | 35.61 | ― | 0.24% | 25.44% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:ALEMBICLTD
Alembic Limited
91.31
-7.72
-7.80%
IN:ALKEM
Alkem Laboratories Ltd.
5,404.05
377.07
7.50%
IN:APLLTD
Alembic Pharmaceuticals Limited
754.50
-139.49
-15.60%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,389.55
151.50
12.24%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,405.55
1,003.24
71.54%
IN:IPCALAB
IPCA Laboratories Limited
1,531.20
143.88
10.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.